Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology; Key Laboratory for Molecular Diagnosis of Hubei Province, Wuhan, People's Republic of China.
Clin Exp Immunol. 2022 Sep 29;209(3):311-315. doi: 10.1093/cei/uxac061.
To explore the relationship between the expression levels of protein tyrosine phosphatase non-receptor type (PTPN) 22.6 mRNA in peripheral blood mononuclear cells (PBMCs) and the disease activity as well as clinical characteristics in Crohn's disease (CD) patients.
A total of 480 subjects were enrolled. Data were collected including baseline information, expression levels of PTPN22.6 mRNA in PBMCs for all subjects, C-reactive protein (CRP) levels in serum, clinical characteristics, and disease activity for all patients. Expression levels of PTPN22.6 mRNA in PBMCs, CRP levels in serum, clinical characteristics according to Montreal Classification [8], and Crohn's disease activity index (CDAI) were the primary observation outcomes.
The expression levels of PTPN22.6 mRNA (P = 0.032) in PBMCs and serum CRP levels (P < 0.001) were significantly higher in active CD patients than in inactive CD patients (P = 0.032). Correlation analysis showed that there was a positive correlation between expression levels of PTPN22.6 mRNA and CDAI value (r = 0.512, P = 0.003), as well as expression levels of PTPN22.6 mRNA and CRP levels in the CD group (r = 0.456, P = 0.006). There were significantly higher expression levels of PTPN22.6 mRNA in PBMCs in patients with structuring behavior than that in patients with non-stricturing and non-penetrating (NSNP) behaviors (P = 0.018) and penetrating behaviors (P = 0.024).
The expression levels of PTPN22.6 mRNA can be used as an indicator to help predict CD diagnosis, disease activity, serum CRP level, and behavior type of CD disease.
探讨外周血单个核细胞（PBMCs）中蛋白酪氨酸磷酸酶非受体型（PTPN）22.6 mRNA 表达水平与克罗恩病（CD）患者疾病活动度及临床特征的关系。
共纳入 480 例受试者。收集所有受试者的基线信息、PBMCs 中 PTPN22.6 mRNA 表达水平、血清 C 反应蛋白（CRP）水平、临床特征和所有患者的疾病活动度等数据。PBMCs 中 PTPN22.6 mRNA 表达水平、血清 CRP 水平、根据蒙特利尔分类[8]的临床特征和克罗恩病活动指数（CDAI）为主要观察终点。
活动期 CD 患者 PBMCs 中 PTPN22.6 mRNA 表达水平（P = 0.032）和血清 CRP 水平（P < 0.001）均显著高于缓解期 CD 患者。相关性分析显示，PBMCs 中 PTPN22.6 mRNA 表达水平与 CDAI 值呈正相关（r = 0.512，P = 0.003），CD 组中 PTPN22.6 mRNA 表达水平与 CRP 水平也呈正相关（r = 0.456，P = 0.006）。结构行为患者 PBMCs 中 PTPN22.6 mRNA 表达水平显著高于非狭窄非穿透（NSNP）行为和穿透行为患者（P = 0.018 和 P = 0.024）。
PBMCs 中 PTPN22.6 mRNA 的表达水平可作为帮助预测 CD 诊断、疾病活动度、血清 CRP 水平和 CD 疾病行为类型的指标。
